Korean Brain Tumor Society Consensus Review for the Practical Recommendations on Glioma Management in Korea

Review Oncology

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

Julie J. Miller et al.

Summary: This article discusses the diagnosis and management of IDH-mutant gliomas, as well as new treatment methods and future research directions.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Oncology

CODEL: phase III study of RT, RT plus TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design

Kurt A. Jaeckle et al.

Summary: The study demonstrated that patients treated with temozolomide alone had significantly shorter progression-free survival (PFS) compared to those receiving radiotherapy. Patients not receiving radiotherapy also had shorter PFS, but there was no significant difference in overall survival. There were no significant differences between groups in terms of adverse events and neurocognitive decline.

NEURO-ONCOLOGY (2021)

添加到收藏夹

Article Oncology

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Michael Weller et al.

Summary: The European Association of Neuro-Oncology (EANO) has released guidelines for the diagnosis, treatment, and follow-up of adult patients with diffuse gliomas, incorporating major changes in diagnostic algorithms based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System, as well as evidence from recent large clinical trials.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Radiosurgery for Glioblastoma

Adomas Bunevicius et al.

NEUROSURGERY CLINICS OF NORTH AMERICA (2021)

添加到收藏夹

Review Oncology

IDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions

Antonio Dono et al.

Summary: This review discusses updates in diagnosis and classification, imaging biomarkers, therapies, and outcomes for IDH-mutant low-grade gliomas. Recent findings suggest that CDKN2A/B homozygous deletion in IDH-mutant astrocytoma is associated with shorter survival, similar to WHO grade 4 tumors. Maximal safe resection is recommended for all LGG cases, and radiotherapy followed by PCV treatment provides longer overall survival compared to radiotherapy alone.

CURRENT ONCOLOGY REPORTS (2021)

添加到收藏夹

Review Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.

NEURO-ONCOLOGY (2021)

添加到收藏夹

Review Oncology